Bet PM

No ORCID on file · 1 paper in corpus
2025
Therapeutics and clinical risk management ·doi:10.2147/tcrm.s273358

IntroductionUlipristal acetate (UPA, 5 mg) demonstrated efficacy in symptom reduction for patients with symptomatic fibroids. While registration and post-marketing trials assessing UPA identified few hepatic concerns, post-marketing concern…